0 (0%) | 03-19 08:59 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 40.69 | 1-year : | 47.52 |
Resists | First : | 34.84 | Second : | 40.69 |
Pivot price | 33.78 | |||
Supports | First : | 33.02 | Second : | 31.9 |
MAs | MA(5) : | 33.99 | MA(20) : | 33.8 |
MA(100) : | 34.26 | MA(250) : | 36.77 | |
MACD | MACD : | 0 | Signal : | 0 |
%K %D | K(14,3) : | 49.5 | D(3) : | 59.2 |
RSI | RSI(14): 47.3 | |||
52-week | High : | 45.13 | Low : | 30.53 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AVA ] has closed above bottom band by 38.8%. Bollinger Bands are 39.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 34.13 - 34.32 | 34.32 - 34.47 |
Low: | 32.87 - 33.14 | 33.14 - 33.36 |
Close: | 33.2 - 33.6 | 33.6 - 33.93 |
Tue, 19 Mar 2024
Forge Biologics' Novel AAV Gene Therapy FBX-101 for Patients with Krabbe Disease is Granted UK's Innovation ... - TT Nyhetsbyrån
Mon, 18 Mar 2024
ReciBioPharma to advance haemophilia treatment with GeneVentiv Therapeutics - BioPharma-Reporter.com
Thu, 14 Mar 2024
Harnessing whole human liver ex situ normothermic perfusion for preclinical AAV vector evaluation - Nature.com
Tue, 12 Mar 2024
A shedding analysis after AAV8 CNS injection revealed fragmented viral DNA without evidence of functional AAV ... - Nature.com
Mon, 11 Mar 2024
What's Next for AAV Gene Therapies in 2024? - Pharmaceutical Technology
Tue, 27 Feb 2024
Bio-Rad Launches Vericheck ddPCR Replication Competent Lentivirus and Replication Competent AAV Kits for Cell ... - The Scientist
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
|
|
Sector:
|
|
Industry:
|
|
Shares Out | 78 (M) |
Shares Float | 77 (M) |
Held by Insiders | 0.8 (%) |
Held by Institutions | 88 (%) |
Shares Short | 2,880 (K) |
Shares Short P.Month | 2,550 (K) |
EPS | 2.24 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 31.82 |
Profit Margin | 9.7 % |
Operating Margin | 18.7 % |
Return on Assets (ttm) | 2.1 % |
Return on Equity (ttm) | 7 % |
Qtrly Rev. Growth | 1.3 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 22.38 |
EBITDA (p.s.) | 6.7 |
Qtrly Earnings Growth | 3.4 % |
Operating Cash Flow | 447 (M) |
Levered Free Cash Flow | -148 (M) |
PE Ratio | 14.99 |
PEG Ratio | 2.2 |
Price to Book value | 1.05 |
Price to Sales | 1.5 |
Price to Cash Flow | 5.87 |
Dividend | 0.46 |
Forward Dividend | 0 |
Dividend Yield | 1.3% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |